Checkpoint Inhibitors in Cancer Care
Jeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
In addition to other immunotherapies, Sosman says he is interested innivolumab and ipilimumab in melanoma
Articles in this issue
A Novel Immunotherapy Demonstrates Durable Responses in Metastatic Melanoma
MPDL3280A Induces Durable Responses in NSCLC, Other Cancers
Immunotherapy—An Increasingly Important Role in Oncology
Suzanne Topalian, MD, on PD-1 Targeted Therapy
Understanding Immunotherapy in Cancer: A Q&A with Antoni Ribas, MD, PhD
PD-1 and PD-L1 Antibodies in Lung Cancer
Checkpoint Inhibitors in Cancer Care
Search for Predictive Biomarkers of PD-1 Pathway Blockade
Nivolumab Plus Ipilimumab in Advanced Melanoma
The Outlook for Immunotherapies
Recent Videos
Related Content
